|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Clinical Therapy Trials—Drug |
The NABTT Central Operations Office, The Johns Hopkins Oncology Center, Baltimore, MD 21287 (J.D.F.); The Johns Hopkins University, Baltimore, MD 21287 (S.A.G., S.P.); Henry Ford Hospital, Detroit, MI 48202 (T.M.); Massachusetts General Hospital, Boston, MA 02114 (F.H.); and Brown University, Providence, RI 02903 (M.G.)
2 Address correspondence and reprint requests to Fred Hochberg, M.D., c/o The NABTT Central Operations Office, The Johns Hopkins Oncology Center, Room 129, 600 North Wolfe St., Baltimore, MD 21287.
Abstract
9-Aminocamptothecin (9-AC) was administered as a 72-h i.v. infusion every 2 weeks to a total of 99 adults with high-grade astrocytomas. Fifty-one patients with newly diagnosed glioblastoma multiforme received 9-AC treatment prior to radiation therapy and 48 patients with high-grade astrocytomas were treated at the time of tumor recurrence. Upon entrance into these research protocols, all patients had measurable disease that was evaluated on a monthly basis with volumetric CT or MRI scans. A partial response was defined by 350% reduction in the contrast enhancing volume on stable or decreasing doses of glucocorticoids. The study specified that all apparent responders would have central review of their radiologic studies and histopathology. The initial patients treated with 9-AC were also receiving anticonvulsants and were noted to have minimal myelosuppression with this chemotherapy. Thus, 9-AC doses were escalated from the previously reported maximum tolerated dose (MTD) of 850 µg/m2/24 h. We then established new MTDs for patients receiving enzyme-inducing anticonvulsants. We defined these MTDs to be 1776 µg/m2/24 h for newly diagnosed, previously untreated patients and 1611 µg/m2/24 h for patients with recurrent disease. Twenty-two patients with newly diagnosed glioblastoma multiforme received 9-AC at doses 31776 µg/m2/24 h. Of these, 18 had evaluable disease on central review, and 0 of 18 (0%) demonstrated a partial or complete response. Twenty-one patients with recurrent high-grade astrocytomas were treated at 1611 µg/m2/24 h; 20 had evaluable disease and 0 of 20 (0%) had a partial or complete response. Thus, the overall response rate in the 38 evaluable patients treated at the MTD was 0 of 38 (0%). Furthermore, of the 51 evaluable patients who were treated at doses less than the MTD, only one partial response was observed, yielding an overall response rate of 2%. Evidence of drug failure was rapid with tumor progression in one-half of patients after 2 drug cycles. 9-AC lacks evidence of substantial activity in patients with newly diagnosed or recurrent high-grade astrocytomas.
References
Bahemuka, M., Massey, E.W., and Schoenberg, B.S.
(1988) International mortality from primary nervous system
neoplasms: Distributions and trends. Int. J. Epidem.
17, 33-38.
Burris, H.A., Rothenberg, M.L., Kuhn, J.G., and Von Hoff, D.D. (1992) Clinical trails with topoisomerase I inhibitors. Semin. Oncol. 19,663 -669.[Web of Science][Medline]
Dahut, W., Brillhart N., Takimoto, C., Allegra, C., Hamilton, J.M., Sorenson, J.M., Arbuck, S., Chen, A., and Grem, J. (1994) A Phase I trial of 9-aminocamptothecin (9-AC) in adult patients with solid tumors. Proc. Am. Soc. Clin. Oncol. 13, 138. (Abstract)
Eder, J.P, Jr., Supko, J.G., Lynch, T., Bryant, M., Vosburgh, E.,
Shulman, L.N., Xu, G., and Kufe, D.W. (1998) Phase I trial of the
colloidal dispersion formulation of 9-amino-20 (S)-camptothecin administered
as a 72-hour continuous intravenous infusion. Clin. Cancer
Res. 4,317
-324.
Fetell, M.R., Grossman, S.A., Fisher, J.D., Erlanger, B., Rowinsky, E., Stockel, J., and Piantadosi, S. (1997) Preirradation paclitaxel in glioblastoma multiforme: Efficacy, pharmacology, and drug interactions. J. Clin. Oncol. 15,3121 -3128.[Abstract]
Giovanella, B.C., Stehlin, J.S., Wall, M.E., Wani, M.C., Nicholas, A.W, Liu, L.F., Silber, R., and Potmesil, M. (1989) DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts.Science (Washington) 246,1046 -1048.
Grossman, S.A, Brem, H., Piantadosi, S., and Fisher, J. (1998) The NABTT CNS Consortium: Organization, objectives and progress. Cancer Control 5, 107-114.[Web of Science][Medline]
Grossman, S.A., Hochberg, F., Fisher, J.D., Chen, T.L., Kim, L., Gregory, R., Grochow, L.B., and Piantadosi, S. (1998) Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The New Approaches to Brain Tumor Therapy. Cancer Chemother. Pharmacol. 42,118 -126.[CrossRef][Web of Science][Medline]
Hertzberg, R.P., Caranfa, M.J., and Hecht, S.M. (1989) On the mechanism of topoisomerase I inhibition by camptothecin: Evidence for binding to an enzyme-DNA complex. Biochemistry 28,4629 -4638.[CrossRef][Medline]
Hsiang, Y.H, Hertzberg, R., Hecht, S., and Liu, L.F.
(1985) Camptothecin induces protein-linked DNA breaks via
mammalian DNA topoisomerase I. J Biol. Chem.
260,14873
-14878.
Horowitz, S.B., and Horowitz, M.S. (1973) Effects of
camptothecin on the breakage and repair of DNA during the cell cycle.
Cancer Res. 33:2834
-2836.
Kim, L., Hochberg F.H., Thornton, A.F., Harsh, G.R. IV, Patel, H., Finkelstein, D., and Louis, D.N. (1996) Procarbazine, lomustine, and vincristine chemotherapy for grade III and grade IV oligoastrocytomas. J. Neurosurg. 85,602 -607.[Web of Science][Medline]
Liu, L.F. (1989) DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 58,351 -375.[CrossRef][Web of Science][Medline]
Muggia, F.M., Creaven, P.J., Hansen, H.H., Cohen, M.H., and Selawry, O.S. (1972) Phase I trial of weekly and daily treatment with camptothecin (NSC-100880): Correlation with preclinical studies. Cancer Chemother. Rep. (Pt. 1) 56,515 -521.[Web of Science][Medline]
Pantazis, P., Hinz, H.R, Mendoza, J.T., Kozielski, A.J., Williams,
L.J., Jr., Stehlin, J.S., Jr., and Giovanella, B.C. (1992)
Complete inhibition of growth followed by death of human malignant melanoma
cells in vitro and regression of human melanoma xenografts immunodeficient
mice induced by camptothecins. Cancer Res.
52,3980
-3987.
Piantadosi, S., Fisher, J.D., and Grossman, S.A. (1998) Practical implementation of a modified continual reassessment method for dose-finding trials. Cancer Chemother. Pharmacol. 41,429 -436.[CrossRef][Web of Science][Medline]
Potmesil, M., Giovanella, B.C., and Lui, L.F. (1991) Preclinical studies of DNA topoisomerase I- targeted 9-amino and 10, 11-methylenedioxycamptothecin. In: Potmesil, M., and Kohn, K.W. (Eds.), DNA Topoisomerases in Cancer. New York: Oxford University Press. pp. 283-298.
Potmesil, M., Giovanella, B.C., Wall, M.E. (1993) Preclinical and clinical development of DNA topoisomerase I inhibitors in the United States. In: Andoh, T. (Ed.), Molecular Biology of DNA Topoisomerases and Its Application to Chemotherapy. International Symposium on DNA Topoisomerases in Chemotherapy. Boca Raton: CRC Press. pp.301 -311.
Rubin, E., Wood, V., Bharti, A., Trites, D., Lynch, C., and Kufe, D. (1994) A Phase I trial of 9-aminocamptothecin (9-AC). Proc. Am. Assoc. Cancer Res. 35, 245. (Abstract)
Takimoto, C.H, Klecker, R.W., Dahut, W.L., Yee, L.K., Strong, J.M., Allegra, C.J., and Grem, J.L. (1994) Analysis of the active lactone form of 9-aminocamptothecin in plasma using solid-phase extraction and high-performance liquid chromatography. J. Chromatogr. B Biomed. Appl. 655,97 -104.[CrossRef][Web of Science][Medline]
Takimoto, C.H., Dahut, W., Marino, M.T., Nakashima, H., Liang, M.D., Harold, N., Lieberman, R., Arbuck, S.G., Band, R.A., Chen, A.P., Hamilton, J.M., Cantilena, L.R., Allegra, C.J., and Grem, J.L. (1997) Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients. J. Clin. Oncol. 15,1492 -1501.[Abstract]
CiteULike 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Lustig, T. Mikkelsen, G. Lesser, S. Grossman, X. Ye, S. Desideri, J. Fisher, J. Wright, and the New Approaches to Brain Tumor Therapy CNS Cons Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease Neuro-oncol, January 1, 2008; 10(6): 1004 - 1009. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Carson, S. A. Grossman, J. D. Fisher, and E. G. Shaw Prognostic Factors for Survival in Adult Patients With Recurrent Glioma Enrolled Onto the New Approaches to Brain Tumor Therapy CNS Consortium Phase I and II Clinical Trials J. Clin. Oncol., June 20, 2007; 25(18): 2601 - 2606. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
